Adequate period of surveillance in each stage for curatively resected gastric cancer: analyzing the time and rates of recurrence.
Curative resection
Gastrectomy
Gastric cancer
Recurrence
Surveillance
Journal
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
ISSN: 1436-3305
Titre abrégé: Gastric Cancer
Pays: Japan
ID NLM: 100886238
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
received:
05
06
2020
accepted:
08
12
2020
pubmed:
6
1
2021
medline:
21
12
2021
entrez:
5
1
2021
Statut:
ppublish
Résumé
Surveillance after curative surgery for gastric cancer is conventionally performed for 5 years. However, the appropriate follow-up period remains controversial. This study retrospectively compiled a clinicopathological database of patients who underwent curative gastrectomy between 1975 and 2010 at Toranomon Hospital and were reviewed until March 2020. Analyzing the follow-up rate and recurrence rate for each stage in each postoperative year, we set each follow-up endpoint when the subsequent recurrence rate fell below 1%. A total of 5235 patients were eligible for inclusion in the study. The rate of patients followed up for 5 years was 90.3%. The rates of follow-up were 52.7% at 10 years, 38.3% at 15 years, and 10.3% at 20 years. Recurrence was confirmed in 850 patients in total (16.2%) and in 50 patients beyond 5 years. The adequate follow-up endpoints according to stage (with < 1% recurrence risk) were 2 years for stage IA, 4 years for IB, 6 years for IIA, 9 years for IIB, 7 years for IIIA, and 8 years for IV (curative). For stage IIIB and IIIC, the recurrence risk remained. The adequate surveillance duration of resected gastric cancer might be different in each stage. Although the follow-up duration for stage I disease could be reduced to less than 5 years, advanced gastric cancer such as stage III or IV disease has risk of recurrence beyond 5 years and therefore additional follow-up is required. These results could help decide the strategy for surveillance.
Sections du résumé
BACKGROUND
BACKGROUND
Surveillance after curative surgery for gastric cancer is conventionally performed for 5 years. However, the appropriate follow-up period remains controversial.
METHODS
METHODS
This study retrospectively compiled a clinicopathological database of patients who underwent curative gastrectomy between 1975 and 2010 at Toranomon Hospital and were reviewed until March 2020. Analyzing the follow-up rate and recurrence rate for each stage in each postoperative year, we set each follow-up endpoint when the subsequent recurrence rate fell below 1%.
RESULTS
RESULTS
A total of 5235 patients were eligible for inclusion in the study. The rate of patients followed up for 5 years was 90.3%. The rates of follow-up were 52.7% at 10 years, 38.3% at 15 years, and 10.3% at 20 years. Recurrence was confirmed in 850 patients in total (16.2%) and in 50 patients beyond 5 years. The adequate follow-up endpoints according to stage (with < 1% recurrence risk) were 2 years for stage IA, 4 years for IB, 6 years for IIA, 9 years for IIB, 7 years for IIIA, and 8 years for IV (curative). For stage IIIB and IIIC, the recurrence risk remained.
CONCLUSIONS
CONCLUSIONS
The adequate surveillance duration of resected gastric cancer might be different in each stage. Although the follow-up duration for stage I disease could be reduced to less than 5 years, advanced gastric cancer such as stage III or IV disease has risk of recurrence beyond 5 years and therefore additional follow-up is required. These results could help decide the strategy for surveillance.
Identifiants
pubmed: 33400037
doi: 10.1007/s10120-020-01147-4
pii: 10.1007/s10120-020-01147-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
752-761Commentaires et corrections
Type : ErratumIn
Références
D’Ugo D, Biondi A, Tufo A, Persiani R. Follow-up: the evidence. Dig Surg. 2013;30:159–68.
doi: 10.1159/000350878
Kim H, Han S, Kim M, Hyung WJ, Kim W, Lee HJ, et al. Long-term results of laparoscopic gastrectomy for gastric cancer: a large-scale case-control and case-matched Korean multicenter study. J Clin Oncol. 2014;32:627–33.
doi: 10.1200/JCO.2013.48.8551
Shinohara T, Satoh S, Kanaya S, Ishida Y, Taniguchi K, Isogaki J, et al. Laparoscopic versus open D2 gastrectomy for advanced gastric cancer: a retrospective cohort study. Surg Endosc. 2013;27:286–94.
doi: 10.1007/s00464-012-2442-x
Fang C, Hua J, Li J, Zhen J, Wang F, Zhao Q, et al. Comparison of long-term results between laparoscopy-assisted gastrectomy and open gastrectomy with D2 lymphadenectomy for advanced gastric cancer. Am J Surg. 2014;208:391–6.
doi: 10.1016/j.amjsurg.2013.09.028
Sato H, Shimada M, Kurita N, Iwata T, Nishioka M, Morimoto S, et al. Comparison of long-term prognosis of laparoscopy-assisted gastrectomy and conventional open gastrectomy with special reference to D2 lymph node dissection. Surg Endosc. 2012;26:2240–6.
doi: 10.1007/s00464-012-2167-x
National Comprehensive Cancer Network. Gastric cancer NCCN Guidelines. Available from: URL: https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf .
Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D. Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27:v38-49.
doi: 10.1093/annonc/mdw350
De Manzoni G, Marrelli D, Baiocchi GL, Morgagni P, Saragoni L, Degiuli M, et al. The Italian research group for gastric cancer (GIRCG) guidelines for gastric cancer staging and treatment 2015. Gastric Cancer. 2017;20:20–30.
doi: 10.1007/s10120-016-0615-3
Institut National du Cancer. Tumeur maligne, affection maligne du tissue lymphatique ou hématopoïétique. Available from: http://www.has-sante.fr/portail/upload/docs/application/pdf/2011-10/ald_30_gm_k_estomac_web.pdf .
Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer. 2017;20:1–19.
doi: 10.1007/s10120-016-0622-4
Lee JH, Kim HI, Kim MG, Ha TK, Jung MS, Kwon SJ. Recurrence of gastric cancer in patients who are disease-free for more than 5 years after primary resection. Surgery. 2016;159:1090–8.
doi: 10.1016/j.surg.2015.11.002
Maehara Y, Okuyama T, Oshiro T, Baba H, Adachi Y, Sugimachi K. Analysis of 390 patients surviving 10 years or longer after curative resection for gastric cancer. Oncology. 1994;51:366–71.
doi: 10.1159/000227367
Kang WM, Meng QB, Yu JC, Ma ZQ, Li ZT. Factors associated with early recurrence after curative surgery for gastric cancer. World J Gastroenterol. 2015;21:5934–40.
doi: 10.3748/wjg.v21.i19.5934
Bilici A, Selcukbiricik F. Prognostic significance of the recurrence pattern and risk factors for recurrence in patients with proximal gastric cancer who underwent curative gastrectomy. Tumour Biol. 2015;36:6191–9.
doi: 10.1007/s13277-015-3304-7
Cardoso R, Coburn NG, Seevaratnam R, Mahar A, Helyer L, Law C, et al. A systematic review of patient surveillance after curative gastrectomy for gastric cancer: a brief review. Gastric Cancer. 2012;15(Suppl 1):S164–7.
doi: 10.1007/s10120-012-0142-9
Tan IT, So BY. Value of intensive follow-up of patients after curative surgery for gastric carcinoma. J Surg Oncol. 2007;96:503–6.
doi: 10.1002/jso.20823
Park CH, Park JC, Chung H, Shin SK, Lee SK, Cheong JH, et al. Impact of the surveillance interval on the survival of patients who undergo curative surgery for gastric cancer. Ann Surg Oncol. 2016;23:539–45.
doi: 10.1245/s10434-015-4866-8
Renehan AG, Egger M, Saunders MP, O’Dwyer ST. Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials. BMJ. 2002;324:813.
doi: 10.1136/bmj.324.7341.813
Figueredo A, Rumble RB, Maroun J, Earle CC, Cummings B, McLeod R, et al. Follow-up of patients with curatively resected colorectal cancer: a practice guideline. BMC Cancer. 2003;3:26.
doi: 10.1186/1471-2407-3-26
Jeffery M, Hickey BE, Hider PN. Follow-up strategies for patients treated for nonmetastatic colorectal cancer. Cochrane Database Syst Rev. 2007;9:CD002200.
Tjandra J, Chan MK. Follow-up after curative resection of colorectal cancer: a meta-analysis. Dis Colon Rectum. 2007;50:1783–99.
doi: 10.1007/s10350-007-9030-5
Japanese Society for Cancer of the Colon and Rectum. Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines. for treatment of colorectal cancer. Int J Clin Oncol. 2014;25(20):207–39.
Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14:101–12.
doi: 10.1007/s10120-011-0041-5
Whiting J, Sano T, Saka M, Fukagawa T, Katai H, Sasako M. Follow-up of gastric cancer: a review. Gastric Cancer. 2006;9:74–81.
doi: 10.1007/s10120-006-0360-0
Shiraishi N, Inomata M, Osawa N, Yasuda K, Adachi Y, Kitano S. Early and late recurrence after gastrectomy for gastric carcinoma univariate and multivariate analyses. Cancer. 2000;89:255–61.
doi: 10.1002/1097-0142(20000715)89:2<255::AID-CNCR8>3.0.CO;2-N
Kodera Y, Ito S, Yamamura Y, Mochizuki Y, Fujiwara M, Hibi K, et al. Follow-up surveillance for recurrence after curative gastric cancer surgery lacks survival benefit. Ann Surg Oncol. 2003;10:898–902.
doi: 10.1245/ASO.2003.12.009
Lai JF, Kim S, Kim K, Li C, Oh SJ, Hyung WJ, et al. Prediction of recurrence of early gastric cancer after curative resection. Ann Surg Oncol. 2009;16:1896–902.
doi: 10.1245/s10434-009-0473-x
Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D, et al; ESMO Guidelines Committee. ESMO Guidelines Committee (2016) Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27:38–49.
Moon YW, Jeung HC, Rha SY, Yoo NC, Roh JK, Noh SH, et al. Changing patterns of prognosticators during 15-year follow-up of advanced gastric cancer after radical gastrectomy and adjuvant chemotherapy: a 15-year follow-up study at a single Korean institute. Ann Surg Oncol. 2007;14:2730–7.
doi: 10.1245/s10434-007-9479-4
Paoletti X, Oba K, Burzykowski T, Michiels S, Ohashi Y, Pignon JP, et al; The GASTRIC Group. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA. 2010;303:1729–37.
doi: 10.1001/jama.2010.534
Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al; ACTS-GC Group. Adjuvant chemotherapy for gastric cancer with S, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810–20.
doi: 10.1056/NEJMoa072252